Showing results (351-360 of 577) with videos related to

Sort By:
Pageof 58
Journal of the National Cancer Institute|October 30, 2012
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancerArnaud D Roth, Mauro Delorenzi, Sabine Tejpar, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 22, 2021
227Th-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I StudyOla Lindén, Andrew T Bates, David Cunningham, et al.
The Oncologist|May 7, 2017
Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant ChemoradiotherapyFrancesco Sclafani, Gina Brown, David Cunningham, et al.
Clinical Pharmacokinetics|September 6, 2015
Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic MalignanciesElodie Odore, François Lokiec, Esteban Cvitkovic, et al.
World Journal of Nuclear Medicine|July 22, 2022
The Diagnostic Accuracy of 18 F-FGD-PET/CT for Cancer of the Gallbladder: A Retrospective StudyStephanos Pericleous, Sophie L F Doran, Andrew Wotherspoon, et al.
International Journal of Radiation Oncology, Biology, Physics|June 3, 2015
Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C TrialFrancesco Sclafani, Clare Peckitt, David Cunningham, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|June 28, 2020
Histological intratumoral heterogeneity in pretreatment esophageal cancer biopsies predicts survival benefit from neoadjuvant chemotherapy: results from the UK MRC OE02 trialNaser Davarzani, Lindsay C Hewitt, Matthew D Hale, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2005
Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancerIan Chau, Andrew R Norman, David Cunningham, et al.
Clinical Colorectal Cancer|November 14, 2017
Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control StudyHamzeh Kayhanian, Emily Goode, Francesco Sclafani, et al.
JAMA Oncology|December 6, 2016
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical TrialManish A Shah, Yung-Jue Bang, Florian Lordick, et al.
Pageof 58